Background The phase 3 EMERALD trial (NCT03778931) reported significantly prolonged progression- … +)/HER2-negative (HER2–) metastatic breast cancer (mBC) and tumors harboring ESR1 … /AKTi, chemotherapy, or antibody-drug conjugate-based regimens.

… metastatic breast cancer, she admitted she only knew of it from the pharmaceutical … breast cancer can affect anyone at any time, even years after successful treatment … . 30% of early-stage breast cancer will come back …

… to the most effective treatment options, and their … with early breast cancer in Canada.” NATALEE Trial Overview and … patient-reported outcomes, and pharmacokinetics. Additional Efficacy and Safety … Med. 2024;390(12):1080-1091.doi:10.1056/NEJMoa2305488 FDA …

… (THP) in HER2-positive metastatic breast cancer following the readout of data … 3 DESTINY-Breast09 trial (NCT04784715). In the current landscape, treatment decisions are … repositioned within a more tailored treatment paradigm. As sequencing strategies evolve …

… breast cancer treatment. During the interview, McGuinness highlighted the SERENA-6 trial … treatment is a combination of an aromatase inhibitor (an anti-estrogen medication … reviewed by the FDA before we can … breast cancer, so we'd first need drug …

… the NIH and FDA—is quietly leading … Medicine Oncology Pharmacist Precision medicine oncology pharmacists are playing … safer, more effective treatment as precision oncology continues … clinical practice. How Firsthand Breast Cancer Experience Shaped a Surgeon …

… patients with triple-negative breast cancer (TNBC), extensive data … having both antibody-drug conjugates [ADCs] as treatment options for … we’re giving these drugs to, we have to … breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial …

The U.S. Food and Drug Administration (FDA) approved updated labeling for Talzenna … phase 3 TALAPRO-2 trial evaluated treatment for metastatic castration-resistant … single treatment for adults with HER2-negative locally advanced or metastatic breast cancer …

… different options available [after treatment with an] AI … hormone receptor–positive breast cancer whose progression is … placebo-controlled trial, patients were taking 3 pills. They were … breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial …

… aggressive types of breast cancer, particularly triple-negative breast cancer. Unlike traditional vaccines … an early phase one clinical trial” to explore a promising … crucial in triple-negative breast cancer, where treatment options are limited due …